January is when most specialty labs start commercial planning. Pull Q4 numbers. Review ordering physician data. Break revenue down by test category. Start projecting forward.
That process isn't wrong — it's just incomplete. And the thing it's missing is the thing that will quietly constrain growth all year: market-level collection performance data.
An aggregate completion rate tells you almost nothing useful for planning. It hides the market where you're running 20 points below your best geography. It hides the ordering physician cluster that quietly stopped referring six months ago because collections kept coming back incomplete. It hides the rural counties where your test is technically available but practically inaccessible because there's no qualified draw site anywhere near the patients who need it.
Plans built on aggregate data are plans built on averages. And averages, in this context, are a comfortable way to miss what's actually happening.
These aren't KPIs for a dashboard. They're the specific data points that tell you where your 2027 commercial plan is going to hit friction — before it does.
Pull your completion data for the last 12 months. Break it down — by MSA, by ordering physician cluster, by the geographies your commercial team actually manages against. Not just by state.
In almost every lab's data, there are two or three markets running meaningfully below the aggregate. Those markets aren't growing proportionally to your physician penetration because the collection infrastructure isn't keeping up with demand. That gap between what your commercial team sold and what the network delivered is where the 2027 infrastructure conversation starts.
Physicians who get reliable results refer consistently. The ones who don't — or who get inconsistent results because collection is unreliable — quietly shift volume somewhere else.
The attrition is usually invisible in aggregate referral data because it's slow and spread out. It shows up as a market that isn't growing the way your sales data would predict. Or a set of physicians who are listed as 12-month active in your CRM but whose actual order volume has been drifting down for two quarters.
Mapping retention rate against collection performance by market tells you which markets you're losing and why. That's not a comfortable analysis. It's a necessary one.
Pull your ordered volume for Q3 and Q4 last year. Pull your completed volume for the same period. The difference — the orders that were placed but never resulted in a completed draw — is revenue that didn't reach your income statment.
That gap is most visible in markets where collection infrastructure is thinnest. And it's the number that makes an infrastructure investment conversation straightforward: this is what we left on the table, and this is what closing that gap is worth.
The window between Thanksgiving and year-end is effectively closed for major commercial decisions. Most labs aren't making infrastructure investments in December — focus is on Q4 close, year-end reporting, getting ready for January.
November is the last real window for a different kind of decision-making. Q4 data is nearly complete. The 2027 planning cycle hasn't locked yet. There's still time to act on what you find, not just document it.
Labs that run this analysis in November can make 2027 infrastructure decisions — which markets to prioritize, which collection gaps to close, which partner relationships to formalize — before the year ends. Labs that wait until January are making decisions after Q4 results are already baked in.
The challenge is that market-level collection data doesn't live in one place. Ordered volume is in the LIS. Completion data may be in a separate system. Draw site coverage requires overlaying your ordering physician distribution against your MAP network — a geographic analysis most labs haven't rune explicitly.
MOMS surfaces this through the platform relationship. When a specialty lab connects to the MOMS network, that data becomes visible: active MAP locations mapped against the lab's commercial markets, completion rates tracked at the draw level, and Sticklogistics® protocol compliance documented for every active collection.
The 2027 commercial plan built on that data is a different document than the one built without it. It has real numbers where the generic plan has assumptions. It has specific markets to prioritize where the generic plan has projections. It has an infrastructure strategy where the generic plan has a gap.
The labs going into 2027 differently are running this analysis now. They're identifying markets where completion rates are constraining growth. They're closing MAP coverage gaps in geographies where physician penetration has outrun collection capacity. They're entering Q1 with infrastructure in place.
Six weeks. That's what's left before the planning window closes.
View the MOMS MAP Network coverage — active MAPs across all 50 states, by state, by MSA, by the markets your 2027 plan depends on ➡️ https://www.myonemedicalsource.com/map-network-coverage